Cargando…

Effectiveness of Osteoporosis Drug in Postmenopausal Women with Spinal Compression Fracture: Combined Consecutive Therapy of Teriparatide and Raloxifene versus Bisphosphonate Single

OBJECTIVE: Bisphosphonate, a typical bone resorption inhibitor, is an important first-line drug for treating osteoporosis. Recent studies show a novel paradigm in stimulating bone formation. Teriparatide, which is composed of recombinant human parathyroid hormone, stimulates osteoblasts and induces...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Chang Jin, Kim, Sion, Choi, Chun Sik, Shin, Hyun Chul, Kwon, Young Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neurotraumatology Society 2016
Materias:	Clinical Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110901/ https://www.ncbi.nlm.nih.gov/pubmed/27857920 http://dx.doi.org/10.13004/kjnt.2016.12.2.123

Ejemplares similares

The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis
por: Ouyang, YuLong, et al.
Publicado: (2021)

Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis
por: Lu, Hsing-Fang, et al.
Publicado: (2020)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
por: Weigl, Moritz, et al.
Publicado: (2021)

Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis
por: Fan, Guiyong, et al.
Publicado: (2020)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
por: Jakob, F, et al.
Publicado: (2012)

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
por: Jakob, F, et al.
Publicado: (2012)

Comparison of the Prescribing Pattern of Bisphosphonate and Raloxifene in Korean Women with Osteoporosis: From a National Health Insurance Claims Database
por: Kim, Jungmee, et al.
Publicado: (2015)

The efficacy of osteoporotic treatment in patients with new spinal vertebral compression fracture pain, ADL, QOL, bone metabolism and fracture-healing - In comparison with weekly teriparatide with bisphosphonate
por: Shigenobu, Keiichi, et al.
Publicado: (2019)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?
por: Ohtori, Seiji, et al.
Publicado: (2017)

Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis
por: Taheri, Saeed, et al.
Publicado: (2019)

Effect of teriparatide (rh-PTH 1–34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study
por: Iwata, Akira, et al.
Publicado: (2017)

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

Teriparatide treatment for postmenopausal women with sacral insufficiency fracture
por: Kim, Young-Hoon
Publicado: (2023)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
por: Fujiwara, Saeko, et al.
Publicado: (2014)

Role of Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures: A Literature Review
por: Imam, Bashir, et al.
Publicado: (2019)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007)

Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis
por: Islander, Ulrika, et al.
Publicado: (2011)

Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
por: Chen, Mingsheng, et al.
Publicado: (2016)

Reply on “teriparatide treatment for postmenopausal women with sacral insufficiency fracture”
por: Yang, Yao-Chun, et al.
Publicado: (2023)

Effectiveness of Weekly Teriparatide Injection in Postmenopausal Patients with Hip Fractures
por: Lee, Sang Yeob, et al.
Publicado: (2023)

Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates
por: Foster, Shonda A, et al.
Publicado: (2008)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
por: Bock, Oliver, et al.
Publicado: (2008)

Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?
por: Bandeira, Francisco, et al.
Publicado: (2020)

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
por: Satterwhite, Julie, et al.
Publicado: (2010)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study
por: Yang, Tiansong, et al.
Publicado: (2019)

Impact of teriparatide therapy in Indian postmenopausal women with osteoporosis with regard to DXA-derived parameters
por: Sandeep, Nandipati Venkata, et al.
Publicado: (2022)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_svobds06ehcgp3bdmls5edcc8s